Staar Surgical Co.'s stock soared 5.12% in extended trading on Tuesday after the company reported better-than-expected third-quarter earnings and revenue, fueled by strong demand for its implantable lenses.
The eye surgery products maker posted Q3 revenue of $88.59 million, surpassing analysts' consensus estimate of $86.9 million. Adjusted earnings per share came in at $0.33, significantly beating Wall Street's projection of $0.17 per share.
The company's strong Q3 performance was driven by robust sales across its product portfolio. Staar Surgical's gross margin also improved to 77.3% in the quarter, up from 76.3% a year earlier. Looking ahead, the company raised its full-year revenue guidance to a range of $340 million to $345 million, reflecting continued growth momentum.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。